On Monday, Immunome Inc (NASDAQ: IMNM) was -5.33% drop from the session before settling in for the closing price of $20.82. A 52-week range for IMNM has been $5.15 – $25.30.
A company in the Healthcare sector has dropped its sales by -38.15% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 55.57%. With a float of $99.36 million, this company’s outstanding shares have now reached $110.33 million.
Immunome Inc (IMNM) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immunome Inc stocks. The insider ownership of Immunome Inc is 9.94%, while institutional ownership is 80.18%. The most recent insider transaction that took place on Dec 30 ’25, was worth 100,018. In this transaction President and CEO of this company bought 4,729 shares at a rate of $21.15, taking the stock ownership to the 665,254 shares. Before that another transaction happened on Dec 22 ’25, when Company’s Director sold 383,200 for $21.74, making the entire transaction worth $8,330,080. This insider now owns 2,031,181 shares in total.
Immunome Inc (IMNM) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -1.11 earnings per share (EPS) during the time that was less than consensus figure (set at -0.61) by -0.5. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.56 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 55.57% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.68% during the next five years compared to -38.15% drop over the previous five years of trading.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
You can see what Immunome Inc (IMNM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 224.66.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.96, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -2.59 in one year’s time.
Technical Analysis of Immunome Inc (IMNM)
Let’s dig in a bit further. During the last 5-days, its volume was 1.75 million. That was inferior than the volume of 2.11 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 35.33%.
During the past 100 days, Immunome Inc’s (IMNM) raw stochastic average was set at 66.40%, which indicates a significant increase from 6.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.43 in the past 14 days, which was higher than the 1.06 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.65, while its 200-day Moving Average is $11.84. However, in the short run, Immunome Inc’s stock first resistance to watch stands at $20.60. Second resistance stands at $21.48. The third major resistance level sits at $22.12. If the price goes on to break the first support level at $19.08, it is likely to go to the next support level at $18.44. The third support level lies at $17.56 if the price breaches the second support level.
Immunome Inc (NASDAQ: IMNM) Key Stats
There are 91,710K outstanding shares of the company, which has a market capitalization of 2.17 billion. As of now, sales total 9,040 K while income totals -292,960 K. Its latest quarter income was 4,020 K while its last quarter net income were -43,400 K.
